米非司酮联合孕三烯酮胶囊治疗子宫肌瘤的临床观察

Clinical Efficacy of Mifepristone Plus Gestrinone for Hysteromyoma

目的:探讨米非司酮联合孕三烯酮胶囊(内美通)治疗子宫肌瘤的临床疗效。方法:对112例子宫肌瘤患者以随机抽样法进行分组治疗,米非司酮组55例,给予米非司酮治疗3个月;联合用药组57例,给予米非司酮联合孕三烯酮胶囊治疗3个月。治疗前后将患者的子宫容积和最大肌瘤的体积、雌激素、孕激素、血红蛋白进行对比,同时统计患者服药期间的不良反应进行对比分析。结果:3个月后,2组患者的子宫容积、最大肌瘤体积均明显缩小(P<0.05),联合用药组效果优于米非司酮组(P<0.05);雌激素、孕激素和血红蛋白水平均较治疗前明显改善(P<0.05),治疗后2组间比较无显著差异(P>0.05),不良反应比较也无明显差异(P>0.05)。结论:米非司酮和孕三烯酮胶囊联合应用可以有效抑制子宫肌瘤,改善激素水平,效果显著。

OBJECTIVE：To evaluate the clinical efficacy of mifepristone plus gestrinone（nemestran） for hysteromyoma.METHODS： A total of 112 patients with hysteromyoma were randomly assigned to receive mifepristone alone（control group,n=55） or mifepristone plus gestrinone（treatment group,n=57） for 3 months.Before and after treatment,the uterine volume and the volume of the largest myoma,estrogen,progesterone and hemoglobin in the two groups were measured.Meanwhile,the adverse drug reactions in the two groups were evaluated.RESULTS： In both groups,the uterine volume and the volume of the largest myoma after 3-month treatment were significantly diminished as compared with before treatment（P〈0.05） and better improvement was noted in the treatment group than in the control group（P〈0.05）;there was improvement in estrogen,progesterone and hemoglobin as compared with before treatment（P〈0.05）,yet the differences were not statistically significant between the two groups（P〉0.05）;the differences in adverse drug reactions were all not statistically significant between the two groups（P〉0.05）.CONCLUSION： Treatment of patients with hysteromyoma using mifepristone plus gestrinone resulted in remarkable inhibition efficacy on hysteromyoma and improvement of hormonal level.